Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVNO

enVVeno Medical Corp

Apr 29 • 02:42PM ET

11.45

-0.56 -4.66 %

Healthcare • Medical Devices • USA • Nano • NASD

Today, 8:10 AMFDA grants first-ever IDE approval for enVVeno's pivotal study of minimally invasive enVVe venous valve system

Peers: ABT MDT BSX EW ISRG SYK ZBH DXCM GMED TFX

| Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-33.05	Insider Own	8.18%	Shs Outstand	0.66M	Perf Week	-9.13%
Market Cap	7.50M	Forward P/E	-	EPS next Y	-	Insider Trans	-8.60%	Shs Float	0.60M	Perf Month	12.75%
Enterprise Value	-20.01M	PEG	-	EPS next Q	-	Inst Own	28.51%	Short Float	12.69%	Perf Quarter	11.60%
Income	-19.47M	P/S	-	EPS this Y	-	Inst Trans	-3.12%	Short Ratio	4.72	Perf Half Y	-54.57%
Sales	0.00M	P/B	0.28	EPS next Y	-	ROA	-52.26%	Short Interest	0.08M	Perf YTD	1.98%
Book/sh	41.36	P/C	0.27	EPS next 5Y	-	ROE	-56.21%	52W High	196.70 -94.18%	Perf Year	-88.99%
Cash/sh	43.05	P/FCF	-	EPS past 3/5Y	24.52% 34.00%	ROIC	-70.96%	52W Low	8.67 32.06%	Perf 3Y	-91.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.27% 5.83%	Perf 5Y	-94.78%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	28.78%	Oper. Margin	-	ATR (14)	0.84	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.58	EPS Q/Q	52.47%	SMA20	-0.10%	Beta	1.21	Target Price	437.50
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	2.89%	Rel Volume	5.39	Prev Close	12.01
Employees	33	LT Debt/Eq	0.01	Earnings	-	SMA200	-69.58%	Avg Volume	16.13K	Price	11.45
IPO	May 31, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-17.86% -	Trades		Volume	70,449	Change	-4.66%

Today 08:05AM	enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve (ACCESSWIRE)
Mar-27-26 08:30AM	enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System (ACCESSWIRE)
Feb-04-26 08:30AM	enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) -8.21%
Jan-15-26 08:00AM	enVVeno Medical Announces Reverse Stock Split (ACCESSWIRE) -13.18%
Nov-26-25 08:48AM	enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment (ACCESSWIRE) -6.41%
05:00PM	Loading…
Nov-13-25 05:00PM	enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve (ACCESSWIRE) -5.16% -35.68%
Oct-31-25 08:05AM	enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Sep-26-25 08:45AM	enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment (ACCESSWIRE)
Sep-15-25 08:45AM	enVVeno Medical Updates Regulatory Status of VenoValve(R) (ACCESSWIRE) +15.89%
Aug-25-25 08:49AM	NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve (Zacks)
Aug-20-25 07:00AM	enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) (ACCESSWIRE) -72.08%
Aug-15-25 09:21AM	enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (ACCESSWIRE) +9.11%
Aug-06-25 08:30AM	Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency (ACCESSWIRE)
Aug-04-25 09:05AM	enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company (ACCESSWIRE)
Aug-01-25 08:00AM	enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE) +5.64%
08:45AM	Loading…
Jul-22-25 08:45AM	enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (ACCESSWIRE)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jun-06-25 08:05AM	Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (ACCESSWIRE) +10.06%
May-19-25 08:05AM	enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer (ACCESSWIRE)
May-13-25 08:45AM	Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery (ACCESSWIRE) +6.09%
May-01-25 08:05AM	enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 (ACCESSWIRE) +10.33%
Apr-23-25 08:00AM	VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium (ACCESSWIRE)
Apr-16-25 08:30AM	enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment (ACCESSWIRE)
Mar-31-25 09:00AM	The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium (ACCESSWIRE)
Feb-28-25 08:00AM	enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 (ACCESS Newswire) -9.92%
Feb-19-25 09:00AM	enVVeno Medical Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE)
08:45AM	One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum (ACCESSWIRE)
Feb-07-25 09:00AM	Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting (ACCESSWIRE)
Dec-16-24 08:50AM	enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe (ACCESSWIRE)
Nov-27-24 08:30AM	enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website (ACCESSWIRE)
08:30AM	Loading…
Nov-20-24 08:30AM	enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium (ACCESSWIRE) -6.65%
Nov-19-24 08:15AM	enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval (ACCESSWIRE) +9.06%
Oct-31-24 08:35AM	enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year (ACCESSWIRE)
Oct-28-24 08:30AM	enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) (ACCESSWIRE)
Sep-26-24 10:20PM	enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering (ACCESSWIRE) -28.00%
04:05PM	enVVeno Medical Corporation Announces Proposed Public Offering (ACCESSWIRE)
Sep-03-24 09:00AM	enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing (ACCESSWIRE)
Aug-14-24 09:00AM	enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) (ACCESSWIRE)
Aug-01-24 08:05AM	enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jun-25-24 09:00AM	enVVeno Medical to Participate in the Virtual Investor Closing Bell Series (ACCESSWIRE)
Jun-21-24 08:35AM	Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting (ACCESSWIRE) +7.07%
Jun-17-24 12:00PM	New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024 (ACCESSWIRE)
08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-08-24 11:54PM	NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024 (InvestorPlace)
04:15PM	enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-24-24 06:15AM	Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium (ACCESSWIRE) -5.09%
Apr-16-24 09:00AM	New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 (ACCESSWIRE)
Apr-09-24 08:45AM	enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer (ACCESSWIRE)
Mar-15-24 09:00AM	enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity (ACCESSWIRE)
Mar-06-24 08:40AM	Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting (ACCESSWIRE) -7.02%
Feb-29-24 04:15PM	enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (ACCESSWIRE) -6.32%
Feb-20-24 08:30AM	Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024 (ACCESSWIRE) +9.96%
Dec-14-23 11:30AM	enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium (ACCESSWIRE)
Nov-16-23 08:45AM	enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium (ACCESSWIRE) -5.92%
Oct-26-23 08:05AM	enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-12-23 09:00AM	enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE)
Oct-06-23 08:57AM	enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial (ACCESSWIRE) -13.72%
08:56AM	enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve (ACCESSWIRE)
08:55AM	enVVeno Medical Announces Private Placement of $28 Million (ACCESSWIRE)
Jul-31-23 04:45PM	enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE) +5.28%
Jul-14-23 08:05AM	enVVeno Medical to Host Virtual KOL Event on July 18, 2023 (ACCESSWIRE)
Jul-05-23 08:05AM	enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events (ACCESSWIRE) +5.56%
May-01-23 08:00AM	enVVeno Medical Reports First Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-02-23 05:15PM	enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-08-23 09:00AM	enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference (ACCESSWIRE)
Jan-18-23 08:05AM	enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer (ACCESSWIRE)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Nov-17-22 12:00PM	Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues (ACCESSWIRE)
Nov-07-22 08:45AM	enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study (ACCESSWIRE)
Oct-27-22 04:05PM	enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Sep-22-22 08:05AM	enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference (ACCESSWIRE) -6.62%
Sep-21-22 04:01PM	enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency (ACCESSWIRE) -8.97%
Sep-19-22 08:05AM	enVVeno Medical to Host Conference Call and Webcast on September 21, 2022 (ACCESSWIRE)
Sep-12-22 07:00AM	enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE) +6.54%
Aug-16-22 08:05AM	enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations (ACCESSWIRE)
Aug-03-22 04:45PM	enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE) +8.52%
Jul-08-22 08:05AM	enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein (ACCESSWIRE) +12.67%
May-02-22 08:00AM	enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-25-22 03:47PM	Do Institutions Own McDonald's Corporation (NYSE:MCD) Shares? (Simply Wall St.)
Apr-21-22 04:32PM	Statement from McDonald's Corporation in Response to Mr. Icahn's Media Outreach (PR Newswire) +6.36%
03:11PM	Carl Icahn takes on McDonald's over treatment of pigs (American City Business Journals)
11:39AM	Heres how Wolfgang Pucks restaurants have responded to inflation (Yahoo Finance)
08:00AM	Carl C. Icahn Files Definitive Proxy Statement and Issues Open Letter to Shareholders of McDonald's Corporation (Business Wire)
Apr-20-22 02:28PM	McDonald's launches ad campaign to thank its workers (American City Business Journals)
Apr-11-22 08:05AM	enVVeno Medical Announces New U.S. VenoValve(R) Patent (ACCESSWIRE) -5.59%
Mar-28-22 07:05AM	enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update (ACCESSWIRE) +26.67%
Mar-24-22 12:53PM	Inflation hasn't stopped Olive Garden diners from ordering endless breadsticks, salads (Yahoo Finance)
Mar-22-22 12:43PM	Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation (Simply Wall St.)
Mar-09-22 08:35AM	One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery (ACCESSWIRE)
Feb-25-22 08:05AM	Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum (ACCESSWIRE) +10.95%
Feb-16-22 09:05AM	enVVeno Medical Announces ISO 13485 Certification (ACCESSWIRE)
Feb-03-22 05:38PM	Act Capital Management, Llc Buys Adtran Inc, Meta Platforms Inc, Vir Biotechnology Inc, Sells , ... (GuruFocus.com)
Jan-20-22 08:30AM	enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference (ACCESSWIRE)
Jan-12-22 10:35AM	JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th (ACCESSWIRE)
Nov-16-21 08:20AM	enVVeno Medical to Present at the Virtual Investor Roundtable Event (ACCESSWIRE)
Nov-11-21 08:05AM	enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-21 02:30PM	JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th (ACCESSWIRE)
Oct-22-21 09:00AM	enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial (ACCESSWIRE)

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Duhay Francis	Director	Mar 12 '26	Sale	11.52	140	1,613	2,502	Mar 13 04:05 PM
Duhay Francis	Director	Mar 12 '26	Proposed Sale	11.52	140	1,613		Mar 12 12:13 PM
Duhay Francis	Director	Dec 11 '25	Sale	0.36	4,900	1,742	92,544	Dec 12 04:40 PM
Duhay Francis	Director	Sep 15 '25	Sale	0.83	4,900	4,067	97,444	Sep 17 09:00 AM
Duhay Francis	Director	Sep 15 '25	Proposed Sale	0.83	9,800	8,143		Sep 15 11:52 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVNO

enVVeno Medical Corp

Upgrade your Finviz experience